Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05465954
Title Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Mayo Clinic
Indications

IDH-wildtype glioblastoma

gliosarcoma

malignant astrocytoma

glioblastoma

Therapies

NT-I7 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST